Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Long COVID
Cocaine Intoxication
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Monkeypox
Smallpox
COVID-19
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1800
Broad Spectrum Antivirals
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
April 2024
AACR Annual Meeting 2024: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody
April 2024
AACR Annual Meeting 2024: A CXCR4 partial agonist TFF2-MSA improves anti-PD-1 immunotherapy in advanced gastric cancer by selectively targeting PMN-MDSC
April 2024
World Vaccine Congress 2024
March 2024
American Chemistry Society (ACS) Spring 2024
March 2024
Controversies in Fibromyalgia 2024
October 2023
Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in a Preclinical Model
October 2023
Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade–Based Immunosuppression
October 2023
WVC Europe: A Novel Mpox Vaccine (Horsepox Platform) to Enhance Preparedness and Global Vaccine Equity
October 2023
FPWR: A planned phase 2, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of TNX-2900 for the treatment of patients with Prader-Willi syndrome
September 2023
CICON: mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated CT26.WT Subcutaneous and CT26-Luciferase Orthotopic Syngeneic Colorectal Cancer Models by Targeting MDSCs in BALB/C Mice
Posts navigation
Older posts